QNRX — Quoin Pharmaceuticals Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671502 ·
Last close
$6.43
Market Cap
$12.91M
52W High
$41.80
52W Low
$3.25
ADV30
1,123,330
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,473,574 | -5,371,042 | 11,969,562 | 3,845,606 | 8,036,891 |
| Mar 2026 | 0 | — | -5,131,210 | -4,997,735 | 15,692,891 | 3,124,523 | 6,919,759 |
| Dec 2025 | 0 | — | -4,520,435 | -4,348,373 | 20,390,569 | 3,818,096 | 7,270,663 |
| Sep 2025 | 0 | — | -4,019,925 | -3,948,165 | 6,423,664 | 1,830,906 | 7,638,284 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,815,738
Investing CF
$-2,928,861
Financing CF
$18,047,159
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.50
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,968,182
Inventory
—
Receivables
—
ST Investments
$10,918,778
EBIT TTM
$-17,464,749
Pretax Income TTM
$-16,990,211
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,290,716 | -15,804,655 | 20,390,569 | 7,270,663 | 13,119,906 | -13,540,994 |
| Dec 2024 | 0 | -9,528,465 | -8,962,472 | 15,709,338 | 6,504,665 | 9,204,673 | -7,857,309 |
| Dec 2023 | 0 | -9,378,504 | -8,686,573 | 12,169,229 | 6,505,213 | 5,664,016 | -7,864,429 |
| Dec 2022 | 0 | -9,257,704 | -9,381,496 | 14,458,063 | 7,051,289 | 7,406,774 | -8,480,732 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AEON | AEON Biopharma, Inc. | $13.17M | $0.26 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $13.18M | $6.95 | — |
| BLRX | BioLineRx Ltd. | $12.61M | $2.60 | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $13.26M | $0.32 | — |
| GTBP | GT Biopharma, Inc. | $12.43M | $6.89 | — |
News headlines (Yahoo Finance, 1h cache)
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
2026-09-22 12:30 · Yahoo
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
2026-09-10 12:30 · Yahoo
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
2026-09-08 18:12 · Yahoo
Quoin in line for priority review voucher if rare paediatric drug approved
2026-09-08 17:28 · Yahoo
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
2026-08-28 10:00 · Yahoo
QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization
2026-08-27 15:25 · Yahoo
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-14 12:30 · Yahoo
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
2026-07-09 12:30 · Yahoo
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
2026-06-30 12:30 · Yahoo
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
2026-06-23 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.